GlaxoSmithKline Pharmaceuticals Ltd
Company Profile
Business description
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
Contact
Dr. Annie Besant Road
No. 252, GSK House
Worli
MumbaiMH400030
INDT: +91 2224959595
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 March 2027
Employees
3,103
GlaxoSmithKline Pharmaceuticals Ltd News & Analysis
stocks
Best international companies to own: 2023 Edition
stocks
Vaccine rollout and herd immunity to end the pandemic
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,047.30 | 25.90 | -0.29% |
| CAC 40 | 8,453.46 | 14.52 | -0.17% |
| DAX 40 | 25,018.35 | 8.45 | -0.03% |
| Dow JONES (US) | 51,564.70 | 72.15 | 0.14% |
| FTSE 100 | 10,368.13 | 31.57 | -0.30% |
| HKSE | 23,924.81 | 387.35 | -1.59% |
| NASDAQ | 26,517.93 | 496.28 | 1.91% |
| Nikkei 225 | 71,250.06 | 196.57 | 0.28% |
| NZX 50 Index | 13,495.63 | 132.32 | 0.99% |
| S&P 500 | 7,500.58 | 80.48 | 1.08% |
| S&P/ASX 200 | 8,828.70 | 27.90 | -0.32% |
| SSE Composite Index | 4,090.48 | 17.59 | -0.43% |